efpeglenatide vs Liraglutide (Victoza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

efpeglenatide

Marketed by Hanmi Pharmaceutical and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT03353350 · Phase 3 · completed

AMPLITUDE-M was a randomized, double-blind, placebo-controlled Phase 3 trial of once-weekly efpeglenatide 2, 4 or 6 mg as monotherapy in 406 adults with type 2 diabetes not controlled by diet and exercise. The primary endpoint was the change in HbA1c at week 30. Each dose lowered HbA1c significantly more than placebo, by 0.5, 0.8 and 1.0 percentage points (p=0.0054, p<0.0001 and p<0.0001), so the primary endpoint was met. Source: the peer-reviewed trial report.

Next expected readout: November 2027 · NCT07379333 (registry estimate)

Reported efficacy

Change in Glycated Hemoglobin (HbA1c) (%) (Baseline to Week 30): Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care). (met)

Result source: NCT03353350

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT00318461 · Phase 3 · completed

This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.

Next expected readout: June 2027 · NCT03883412 (registry estimate)

Reported efficacy

Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00318461

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointefpeglenatideLiraglutide (Victoza)
HbA1c, change-1.6% vs -0.5%−1.1 vs placebo6 mg · wk 30 · n 103NCT03353350
5 other results
  • -1.5% vs -0.5% 4 mg · wk 30 · n 101 · Phase 3 · primary NCT03353350
  • -1.1% vs -0.5% 2 mg · wk 30 · n 100 · Phase 3 · primary NCT03353350
  • -1.5% vs -0.5% 6 mg · wk 56 · n 103 · Phase 3 · secondary NCT03353350
  • -1.5% vs -0.5% 4 mg · wk 56 · n 101 · Phase 3 · secondary NCT03353350
  • -1.2% vs -0.5% 2 mg · wk 56 · n 100 · Phase 3 · secondary NCT03353350
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422
Body weight, change (kg)-1.8 vs -1.3−0.6 vs placebo6 mg · wk 56 · n 103NCT03353350
5 other results
  • -3.2 vs -1.4 6 mg · wk 30 · n 103 · Phase 3 · secondary NCT03353350
  • -3.2 vs -1.3 4 mg · wk 56 · n 101 · Phase 3 · secondary NCT03353350
  • -3.3 vs -1.4 4 mg · wk 30 · n 101 · Phase 3 · secondary NCT03353350
  • -0.9 vs -1.3 2 mg · wk 56 · n 100 · Phase 3 · secondary NCT03353350
  • -1.0 vs -1.4 2 mg · wk 30 · n 100 · Phase 3 · secondary NCT03353350
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
HbA1c below 7%—Trial running · NCT0737933363.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978
Fasting plasma glucose, change6.5 vs 8.6−2 vs placebo6 mg · wk 30 · n 103NCT03353350
2 other results
  • 6.8 vs 8.6 4 mg · wk 30 · n 101 · Phase 3 · secondary NCT03353350
  • -0.9 vs 8.6 2 mg · wk 30 · n 100 · Phase 3 · secondary NCT03353350
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656
3-point MACE (% with event)—Trial running · NCT0737933313% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048

HbA1c, change

efpeglenatide
-1.6% vs -0.5%−1.1 vs placebo6 mg · wk 30 · n 103NCT03353350
5 other results
  • -1.5% vs -0.5% 4 mg · wk 30 · n 101 · Phase 3 · primary NCT03353350
  • -1.1% vs -0.5% 2 mg · wk 30 · n 100 · Phase 3 · primary NCT03353350
  • -1.5% vs -0.5% 6 mg · wk 56 · n 103 · Phase 3 · secondary NCT03353350
  • -1.5% vs -0.5% 4 mg · wk 56 · n 101 · Phase 3 · secondary NCT03353350
  • -1.2% vs -0.5% 2 mg · wk 56 · n 100 · Phase 3 · secondary NCT03353350
Liraglutide (Victoza)
-0.6% vs 0.4%−1.1 vs placebo1.8 mg · wk 26 · n 66NCT01541215
27 other results
  • -0.6% vs -0.5% 1.8 mg daily · wk 104 · n 235 · Phase 3 · primary NCT00318461
  • -1% vs -1.0% 1.8 mg daily · wk 26 · n 236 · Phase 3 · primary NCT00318461
  • -0.6% vs -0.5% 1.2 mg daily · wk 104 · n 231 · Phase 3 · primary NCT00318461
  • -1.0% vs -1.0% 1.2 mg daily · wk 26 · n 232 · Phase 3 · primary NCT00318461
  • -0.4% vs -0.5% 0.6 mg daily · wk 104 · n 239 · Phase 3 · primary NCT00318461
  • -0.7% vs -1.0% 0.6 mg daily · wk 26 · n 239 · Phase 3 · primary NCT00318461
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · primary NCT02607306
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 151 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -0.7% vs 0.7% 1.8 mg · wk 52 · n 56 · Phase 3 · secondary NCT01541215
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • 7.9% vs 8.9% wk 26 · n 32 · Phase 4 · primary NCT01505673
  • 6.4% vs 6.4% wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -1.1% vs -0.5% wk 26 · n 176 · Phase 4 · primary NCT01907854
  • -1.8% vs -1.2% wk 26 · n 194 · Phase 4 · primary NCT01973231
  • -1.7% vs -1.0% wk 26 · n 162 · Phase 4 · primary NCT02008682
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -1.4% vs -1.1% 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -1.3% vs -0.7% wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.1% vs 0.2% liraglutide 1.2/1.8mg · wk 26 · Phase 3 · primary NCT00318422

Body weight, change (kg)

efpeglenatide
-1.8 vs -1.3−0.6 vs placebo6 mg · wk 56 · n 103NCT03353350
5 other results
  • -3.2 vs -1.4 6 mg · wk 30 · n 103 · Phase 3 · secondary NCT03353350
  • -3.2 vs -1.3 4 mg · wk 56 · n 101 · Phase 3 · secondary NCT03353350
  • -3.3 vs -1.4 4 mg · wk 30 · n 101 · Phase 3 · secondary NCT03353350
  • -0.9 vs -1.3 2 mg · wk 56 · n 100 · Phase 3 · secondary NCT03353350
  • -1.0 vs -1.4 2 mg · wk 30 · n 100 · Phase 3 · secondary NCT03353350
Liraglutide (Victoza)
-2.3 vs 1.0−3.3 vs placebo1.8 mg · wk 52 · n 56NCT01541215
22 other results
  • -2.5 vs -0.9 1.8 mg · wk 26 · n 60 · Phase 3 · secondary NCT01541215
  • -2.9 vs 0.7 1.8 mg daily · wk 104 · n 241 · Phase 3 · secondary NCT00318461
  • -2.8 vs 0.9 1.8 mg daily · wk 26 · n 241 · Phase 3 · secondary NCT00318461
  • -3.0 vs 0.7 1.2 mg daily · wk 104 · n 236 · Phase 3 · secondary NCT00318461
  • -2.6 vs 0.9 1.2 mg daily · wk 26 · n 236 · Phase 3 · secondary NCT00318461
  • -2.1 vs 0.7 0.6 mg daily · wk 104 · n 242 · Phase 3 · secondary NCT00318461
  • -1.8 vs 0.9 0.6 mg daily · wk 26 · n 242 · Phase 3 · secondary NCT00318461
  • 1.2 vs 3 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • 2.9 vs 4.1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1 vs 4.1 wk 52 · n 273 · Phase 3 · secondary NCT02607306
  • 0.2 vs 1.3 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -2.5 vs 1.3 wk 26 · n 151 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • -3.8 vs -3.5 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -3.3 vs -1.8 wk 26 · n 192 · Phase 4 · secondary NCT01907854
  • -4.2 vs -3.7 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -5.4 vs -1.5 wk 4 · n 165 · Phase 4 · secondary NCT01917656
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978

HbA1c below 7%

efpeglenatide
—Trial running · NCT07379333
Liraglutide (Victoza)
63.7% vs 36.5%+27.2 vs placebo1.8 mg · wk 26 · n 66NCT01541215
3 other results
  • 51.8% vs 23.2% wk 26 · n 195 · Phase 3 · secondary NCT02964247
  • 76.5% vs 52.6% wk 26 · n 162 · Phase 4 · secondary NCT02008682
  • 44% vs 20% wk 26 · n 46 · Phase 4 · secondary NCT01966978

Fasting plasma glucose, change

efpeglenatide
6.5 vs 8.6−2 vs placebo6 mg · wk 30 · n 103NCT03353350
2 other results
  • 6.8 vs 8.6 4 mg · wk 30 · n 101 · Phase 3 · secondary NCT03353350
  • -0.9 vs 8.6 2 mg · wk 30 · n 100 · Phase 3 · secondary NCT03353350
Liraglutide (Victoza)
-1.6 vs 1.0−2.6 vs placebo1.8 mg · wk 52 · n 56NCT01541215
21 other results
  • -1.1 vs 0.8 1.8 mg · wk 26 · n 66 · Phase 3 · secondary NCT01541215
  • -1.2 vs -0.6 1.8 mg daily · wk 104 · n 234 · Phase 3 · secondary NCT00318461
  • -1.7 vs -1.3 1.8 mg daily · wk 26 · n 235 · Phase 3 · secondary NCT00318461
  • -1.2 vs -0.6 1.2 mg daily · wk 104 · n 233 · Phase 3 · secondary NCT00318461
  • -1.6 vs -1.3 1.2 mg daily · wk 26 · n 234 · Phase 3 · secondary NCT00318461
  • -0.8 vs -0.6 0.6 mg daily · wk 104 · n 238 · Phase 3 · secondary NCT00318461
  • -1.1 vs -1.3 0.6 mg daily · wk 26 · n 238 · Phase 3 · secondary NCT00318461
  • -3.9 vs -3.7 wk 104 · n 506 · Phase 3 · secondary NCT02501161
  • -4.1 vs -4.0 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -2.6 vs -4.0 wk 52 · n 272 · Phase 3 · secondary NCT02607306
  • -3.6 vs -3.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -1.9 vs -3.5 wk 26 · n 150 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 6.4 vs 6.4 wk 16 · n 15 · Phase 4 · primary NCT02765399
  • -2.2 vs -1.2 1.8 mg · wk 104 · n 996 · Phase 4 · secondary NCT02730377
  • -2.9 vs -1.6 wk 26 · n 194 · Phase 4 · secondary NCT01973231
  • -2.3 vs -1.2 wk 26 · n 168 · Phase 4 · secondary NCT02008682
  • -0.1 vs 0.1 wk 4 · n 146 · Phase 4 · secondary NCT01917656
  • -1.8 vs -0.6 wk 4 · n 143 · Phase 4 · secondary NCT01917656

3-point MACE (% with event)

efpeglenatide
—Trial running · NCT07379333
Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. efpeglenatide: 4 of 4 rows · Liraglutide (Victoza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricefpeglenatideLiraglutide (Victoza)
Dropout rate
21.4%6 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
23.8%4 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
19%2 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
21.1%1.8 mg dailya
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
18.3%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
3%
NCT01179048 · Phase 3
15.2%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
41.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
55.2%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
6.3%
NCT02765399 · Phase 4 · registry result, not featured evidence
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
8.6%
NCT01505673 · Phase 4 · registry result, not featured evidence
7.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
14.7%
NCT02008682 · Phase 4 · registry result, not featured evidence
15.1%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
16.1%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
55.1%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
1.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
3.7%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
2.9%6 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
2%4 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4%2 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
12%1.8 mg dailya
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.5%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT01179048 · Phase 3
0%1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—1.8 mg
NCT01541215 · Phase 3
—
NCT03260881 · Phase 4 · registry result, not featured evidence
7.4%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
7.9%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
—
NCT02765399 · Phase 4 · registry result, not featured evidence
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
—
NCT02014740 · Phase 4 · registry result, not featured evidence
—
NCT02299388 · Phase 4 · registry result, not featured evidence
—
NCT01505673 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01973231 · Phase 4 · registry result, not featured evidence
—
NCT02008682 · Phase 4 · registry result, not featured evidence
6.4%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
—
NCT02889510 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
8.3%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
—
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
—
NCT02964247 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.2%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
—
NCT01937598 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
Serious AEs
6.1%6 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
5.8%4 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.8%2 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.6%1.8 mg dailya
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
10.4%1.2 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%0.6 mg daily
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
49.7%
NCT01179048 · Phase 3
13.6%1.8 mg
NCT01541215 · Phase 3
13.5%1.8 mg
NCT01541215 · Phase 3
4.2%1.8 mg
NCT01541215 · Phase 3
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
38.2%
NCT01919489 · Phase 4 · registry result, not featured evidence · combination
9.4%1.8 mg
NCT02730377 · Phase 4 · registry result, not featured evidence
0%
NCT02765399 · Phase 4 · registry result, not featured evidence
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02014740 · Phase 4 · registry result, not featured evidence
0%
NCT02299388 · Phase 4 · registry result, not featured evidence
2.9%
NCT01505673 · Phase 4 · registry result, not featured evidence
3%
NCT01907854 · Phase 4 · registry result, not featured evidence
5.9%
NCT01973231 · Phase 4 · registry result, not featured evidence
1.6%
NCT02008682 · Phase 4 · registry result, not featured evidence
1.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02889510 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
7.8%Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0%
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.5%
NCT02964247 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
5.1%Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
0%
NCT01937598 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
6 mg
diarrhoea 25.3% (placebo 8.8%)
nausea 22.2% (placebo 2%)
constipation 16.2% (placebo 5.9%)
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
4 mg
diarrhoea 16.5% (placebo 8.8%)
nausea 14.6% (placebo 2%)
constipation 13.6% (placebo 5.9%)
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2 mg
nasopharyngitis 9.8% (placebo 7.8%)
constipation 8.8% (placebo 5.9%)
diarrhoea 8.8% (placebo 8.8%)
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.8 mg dailya
nausea 21.5%
diarrhoea 16.5%
nasopharyngitis 14.9%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 32 more results
1.2 mg daily
nausea 17.5%
nasopharyngitis 15%
headache 14.2%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6 mg daily
nasopharyngitis 17.8%
diarrhoea 12.8%
nausea 12.4%
NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
1.8 mg
nausea 28.8% (placebo 13.2%)
vomiting 25.8% (placebo 8.8%)
diarrhoea 22.7% (placebo 16.2%)
NCT01541215 · Phase 3
1.8 mg
nasopharyngitis 3.8% (placebo 27.9%)
vomiting 3.8% (placebo 8.8%)
abdominal pain 1.9% (placebo 7.4%)
NCT01541215 · Phase 3
1.8 mg
hyperglycaemia 2.1% (placebo 5.9%)
pharyngitis 2.1% (placebo 5.9%)
abdominal pain 0% (placebo 7.4%)
NCT01541215 · Phase 3
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence
1.8 mg
nausea 6.6%
NCT02730377 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 14.3%)
NCT02765399 · Phase 4 · registry result, not featured evidence
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nausea 29.1%
NCT02014740 · Phase 4 · registry result, not featured evidence
nausea 31.4% (placebo 19.4%)
decreased in apetite 17.1% (placebo 11.1%)
diarrhea 11.4% (placebo 8.3%)
NCT01505673 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 16.3%
decreased appetite 8.9%
NCT01907854 · Phase 4 · registry result, not featured evidence
nausea 21.8%
diarrhoea 12.4%
lipase increased 8.4%
NCT01973231 · Phase 4 · registry result, not featured evidence
nausea 14.8%
decreased appetite 10.9%
diarrhoea 8.2%
NCT02008682 · Phase 4 · registry result, not featured evidence
vomiting 5.3%
NCT01917656 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal disorders 27.1% (placebo 5.7%)
general disorders and administration site conditions 2.9% (placebo 0%)
nervous system disorders 2.9% (placebo 2.9%)
NCT02889510 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
decreased appetite 14.4%
diarrhoea 14.4%
lipase increased 12.2%
NCT03172494 · Phase 3 · registry result, not featured evidence
nausea 37.2% (placebo 2.7%)
diarrhea 17.9% (placebo 17.3%)
allergic reaction to liraglutide 1.3% (placebo 0%)
NCT01234649 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nausea 26.2% (placebo 6%)
decreased appetite 9.4% (placebo 0%)
diarrhoea 9.4% (placebo 3%)
NCT02964247 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 34.4%
constipation 13.9%
diarrhoea 8.8%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
headache 12.5% (placebo 12.5%)
asympomatic hyppglycaemia 6.3% (placebo 0%)
nausea 6.3% (placebo 0%)
NCT01937598 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 32 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

efpeglenatide

HbA1c 7.0 or Less 73.8% (n=103) vs 25.5% (n=102) placebo @ 30wk6 mg
event count · % of participants
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 76 Participants as posted
show 2 more results
65.3% (n=101) vs 25.5% (n=102) placebo @ 30wk*4 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 66 Participants as posted
60% (n=100) vs 25.5% (n=102) placebo @ 30wk*2 mg
NCT03353350 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 60 Participants as posted

Liraglutide (Victoza)

MACE 3-point Composite 13% (n=4668) vs 14.9% (n=4672) placebo @ 260wk
event count · % of participants
NCT01179048 · Phase 3
MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
HbA1c Less Than 7% 63.7% (n=66) vs 36.5% (n=68) placebo @ 26wk1.8 mg
responder rate · % of participants
NCT01541215 · Phase 3
show 3 more results
44% (n=46) vs 20% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 26wk
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
76.5% (n=162) vs 52.6% (n=175) Sitagliptin @ 26wk
NCT02008682 · Phase 4 · registry result, not featured evidence
51.79% (n=195) vs 23.16% (n=95) placebo @ 26wk
Yes
NCT02964247 · Phase 3 · registry result, not featured evidence
BMI SDS -0.254 vs -0.208 placebo score @ 26wk1.8 mg
absolute change · score
NCT01541215 · Phase 3
show 1 more result
-0.361 vs -0.166 placebo score @ 52wk1.8 mg
NCT01541215 · Phase 3
HbA1c Less Than 7% 48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 27 Participants as posted
show 8 more results
79.8% (n=341) vs 49.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 272 Participants as posted
53% (n=151) vs 49.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
52.2% (n=289) vs 16.7% (n=138) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 151 Participants as posted
89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted
76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk*
Yes
NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted
71.4% (n=105) vs 21.9% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
79.5% (n=210) vs 68.6% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 167 Participants as posted
66% (n=238) vs 67% (n=233) IGlar + IAsp @ 26wk*
Yes
NCT02420262 · Phase 3 · registry result, not featured evidence · converted to % from 157 Participants as posted
HbA1c Less Than or Equal to 6.5 47.5% (n=59) vs 32.8% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 28 Participants as posted
show 7 more results
44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 25 Participants as posted
58.9% (n=341) vs 28.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 201 Participants as posted
27.2% (n=151) vs 28.7% (n=167) Insulin Degludec @ 26wk*
Yes
NCT03172494 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
33.2% (n=289) vs 7.2% (n=138) Insulin Degludec @ 26wk*
Yes
NCT03175120 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
54.3% (n=105) vs 8.6% (n=105) Insulin Degludec @ 26wk*
Yes
NCT02911948 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
70% (n=210) vs 47.6% (n=210) IGlar @ 26wk*
Yes
NCT02773368 · Phase 3 · registry result, not featured evidence · converted to % from 147 Participants as posted
49.6% (n=238) vs 44.6% (n=233) IGlar + IAsp @ 26wk*
Yes
NCT02420262 · Phase 3 · registry result, not featured evidence · converted to % from 118 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia 52.5% (n=59) vs 36.2% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 31 Participants as posted
show 3 more results
39.3% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 22 Participants as posted
44.7% (n=76) vs 33% (n=88) Glargine @ 26wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
48.2% (n=83) vs 33% (n=94) Glargine @ 12wk*
NCT01919489 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
HbA1c Less Than 7 5 72.9% (n=59) vs 50% (n=58) placebo @ 26wk1.8 mg
event count · % of participants
NCT01541215 · Phase 3 · converted to % from 43 Participants as posted
show 1 more result
64.3% (n=56) vs 44.2% (n=52) placebo @ 52wk*1.8 mg
Yes
NCT01541215 · Phase 3 · converted to % from 36 Participants as posted
SMBG 7-point -2.384 vs 0.198 placebo mmol/L @ 26wk1.8 mg
absolute change · mmol/L
NCT01541215 · Phase 3
show 2 more results
-2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mg
NCT01541215 · Phase 3
-2.25 vs -1.36 Sitagliptin mmol/L @ 26wk
NCT02008682 · Phase 4 · registry result, not featured evidence
PPG Excursion -0.428 vs -0.362 placebo mmol/L @ 26wk1.8 mg
absolute change · mmol/L
NCT01541215 · Phase 3
show 8 more results
-0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mg
NCT01541215 · Phase 3
-0.2 vs 0.09 Insulin Degludec mmol/L @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.54 vs 0.09 Insulin Degludec mmol/L @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.28 vs 0.2 Insulin Glargine mmol/L @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-0.47 vs 0.12 Insulin Glargine mmol/L @ 104wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.76 vs 0.7 Insulin Degludec mmol/L @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence

+ 126 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · Liraglutide (Victoza)'s landscape